| TRADING CENTER |
| Stocks Worth Waiting For - MotleyFool.com | |
| Myriad Genetics to Present at the 28th Annual J.P. Morgan Healthcare Conference - GlobeNewswire | |
| New Zacks.com Research Report for Myriad Genetics, Inc.(MYGN) ($) - Zacks.com | |
| Myriad Genetics Upgraded to Neutral - Analyst Blog - Zacks.com |
| Last trade | Change/%change | P/E ratio | ||
|---|---|---|---|---|
| AMGN | Amgen Inc | 57.22 | 0.49 / 0.86% | 10.94 |
| GILD | Gilead Sciences Inc | 43.24 | 0.08 / 0.19% | 16.69 |
| CELG | Celgene Corporation | 56.29 | 0.20 / 0.36% | 67.82 |
| 2009 Revenue: | $326.5 M | Headquarters: Salt Lake City, UT |
| Employees: | 869 | CEO: Peter D. Meldrum |
| Net Income: | $84.6 M | Industry: Biotechnology |
| Market Cap: | $2.3 B | Website: www.myriad.com |
| Symbol | Price | Change/%Change | Prev. close | High | Low | Last Update | More Info |
|---|---|---|---|---|---|---|---|
| MYGN | 24.92 | +0.76 / +3.15% | 24.16 | 25.07 | 23.96 | Profile Chart News |